Kainova Therapeutics

Immuno-oncology based on G protein-coupled receptor (GPCR)-mediated immunosuppression

Category
Oncology
Location
Montreal, Strasbourg, Boston
Website
Visit website

About the company

Clinical stage company dedicated to disruptive therapies targeting GPCRs in immuno-oncology and inflammation. Lead programs include DT-7012, a Treg-depleting anti-CCR8 antibody, DT-9046, a first-in-class, preclinical, biased PAR2 antagonist for inflammatory diseases, and DT-9081, a Phase II-ready EP4 receptor antagonist for solid tumors